Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Baxalta Incorporated
Yvette Venable has more than 20 years’ experience in patient advocacy, heath policy and biopharma communications.
Evotec is building a gene therapy R&D center manned by ex-Takeda scientists and has already landed a multi-year drug discovery pact for it with their former Japanese employer.
No new patients will be enrolled, and trial participants will stop treatment with the tissue factor pathway inhibitor antibody, a class with four prior suspended hemophilia programs.
Acquired from Novartis last year, Isturisa is forecast to have peak sales of over $100m. Now all eyes will be on a PDUFA date in March.
- Other Names / Subsidiaries
- AesRX LLC
- Chatham Therapeutics
- Gambro AB
- Prism Pharmaceuticals, Inc.
- SuppreMol GmbH
- Synovis Life Technologies, Inc.
- Thunderbolt, Inc.
- Vitesse Biologics, LLC